Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $3.47 billion. The enterprise value is $2.93 billion.
Important Dates
The last earnings date was Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 184.94 million shares outstanding. The number of shares has increased by 0.80% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 184.94M |
| Shares Change (YoY) | +0.80% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 46.80% |
| Float | 81.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 183.82 |
| PS Ratio | 3.37 |
| Forward PS | 2.31 |
| PB Ratio | 3.46 |
| P/TBV Ratio | 3.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.96 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.38 |
Financial Efficiency
Return on equity (ROE) is -29.06% and return on invested capital (ROIC) is -30.47%.
| Return on Equity (ROE) | -29.06% |
| Return on Assets (ROA) | -5.01% |
| Return on Invested Capital (ROIC) | -30.47% |
| Return on Capital Employed (ROCE) | -12.44% |
| Weighted Average Cost of Capital (WACC) | 4.52% |
| Revenue Per Employee | $347,015 |
| Profits Per Employee | -$100,101 |
| Employee Count | 2,965 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 29.44 |
Taxes
In the past 12 months, Legend Biotech has paid $14.20 million in taxes.
| Income Tax | 14.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.97% in the last 52 weeks. The beta is 0.06, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -50.97% |
| 50-Day Moving Average | 19.44 |
| 200-Day Moving Average | 29.58 |
| Relative Strength Index (RSI) | 48.27 |
| Average Volume (20 Days) | 1,838,539 |
Short Selling Information
The latest short interest is 20.05 million, so 20.74% of the outstanding shares have been sold short.
| Short Interest | 20.05M |
| Short Previous Month | 21.87M |
| Short % of Shares Out | 20.74% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.09 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $1.03 billion and -$296.80 million in losses. Loss per share was -$1.62.
| Revenue | 1.03B |
| Gross Profit | 206.10M |
| Operating Income | -136.50M |
| Pretax Income | -282.60M |
| Net Income | -296.80M |
| EBITDA | -127.10M |
| EBIT | -136.50M |
| Loss Per Share | -$1.62 |
Full Income StatementBalance Sheet
The company has $948.60 million in cash and $413.70 million in debt, with a net cash position of $534.90 million or $2.89 per share.
| Cash & Cash Equivalents | 948.60M |
| Total Debt | 413.70M |
| Net Cash | 534.90M |
| Net Cash Per Share | $2.89 |
| Equity (Book Value) | 1.00B |
| Book Value Per Share | 5.42 |
| Working Capital | 610.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.20 million and capital expenditures -$28.60 million, giving a free cash flow of -$128.80 million.
| Operating Cash Flow | -100.20M |
| Capital Expenditures | -28.60M |
| Free Cash Flow | -128.80M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
Gross margin is 20.03%, with operating and profit margins of -13.27% and -28.85%.
| Gross Margin | 20.03% |
| Operating Margin | -13.27% |
| Pretax Margin | -27.47% |
| Profit Margin | -28.85% |
| EBITDA Margin | -12.35% |
| EBIT Margin | -13.27% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.80% |
| Shareholder Yield | -0.80% |
| Earnings Yield | -8.56% |
| FCF Yield | -3.71% |
Analyst Forecast
The average price target for Legend Biotech is $63.08, which is 236.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $63.08 |
| Price Target Difference | 236.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 21.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 4.22 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.22 |
| Piotroski F-Score | 3 |
